Related Experiment Video
Updated: May 13, 2026
09:06
Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease
Published on: June 9, 2018
Biomarkers for Huntington's disease: an update
Rachael I Scahill1, Ed J Wild, Sarah J Tabrizi
1UCL Institute of Neurology, TRACK-HD, Department of Neurodegenerative Disease , Queen Square, London WC1N 3BG , UK.
Expert Opinion on Medical Diagnostics
|March 14, 2013
Summary
Huntington's disease research has advanced significantly, with new biomarkers and outcome measures recommended for future clinical trials. These developments aim to assess the efficacy of emerging therapies for this neurodegenerative condition.
Area of Science:
- Neuroscience
- Genetics
- Biomarker Research
Background:
- Huntington's disease (HD) is an autosomal-dominant neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin gene.
- Current treatments for HD are not disease-modifying, necessitating research into novel therapeutic strategies.
- Previous reviews highlighted the critical need for validated biomarkers in HD research.
Purpose of the Study:
- To provide a systematic update on biomarker development for Huntington's disease since 2008.
- To compare and recommend outcome measures for assessing therapeutic efficacy in HD clinical trials.
- To build upon collaborative research efforts in the field of Huntington's disease.
Main Methods:
- Systematic literature search of the PubMed database.
- Identification and analysis of studies relevant to biomarker development in Huntington's disease.
- Comparison of various outcome measures for their suitability in therapeutic trials.
Main Results:
- Significant advances in Huntington's disease biomarker research have been made since 2008.
- A range of outcome measures are now being recommended for future therapeutic trials.
- Collaborative research has accelerated progress in identifying and validating biomarkers.
Conclusions:
- Validated biomarkers and outcome measures are crucial for evaluating the effectiveness of new Huntington's disease therapies.
- Continued collaborative research is essential for advancing the field and developing disease-modifying treatments.
- The development of standardized outcome measures will facilitate future clinical trials and therapeutic advancements in HD.
Related Concept Videos
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...